NURIX THERAPEUTICS, INC. (NRIX) Shareholder Equity
- 2026-05-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $104.00K; Additional Paid in Capital, Common StockUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-145.00K.
- 2026-02-28: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $103.00K; Additional Paid in Capital, Common StockUSD $1.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $56.00K.
- 2025-11-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $102.00K; Additional Paid in Capital, Common StockUSD $1.54B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $105.00K.
- 2025-08-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $77.00K; Additional Paid in Capital, Common StockUSD $1.30B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $119.00K.
NURIX THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $0.00 | $104.00K | $1.58B | $-145.00K | $-1.18B | $402.63M | (m) | 3 month · $11.40M | (m) |
| 2026-02-28 | $0.00 | $103.00K | $1.57B | $56.00K | $-1.09B | $480.89M | (m) | 3 month · $9.40M | (m) |
| 2025-11-30 | $0.00 | $102.00K | $1.54B | $105.00K | $-1.00B | $538.75M | (m) | 12 month · $37.98M | (m) |
| 2025-08-31 | $0.00 | $77.00K | $1.30B | $119.00K | $-925.00M | $372.25M | (m) | 3 month · $9.78M | (m) |
| 2025-05-31 | $0.00 | $76.00K | $1.29B | $-20.00K | $-838.58M | $447.60M | (m) | 3 month · $10.39M | (m) |
| 2025-02-28 | $0.00 | $76.00K | $1.28B | $226.00K | $-795.12M | $480.92M | (m) | 3 month · $8.73M | (m) |
| 2024-11-30 | $0.00 | $76.00K | $1.27B | $150.00K | $-738.77M | $526.99M | (m) | 12 month · $33.94M | (m) |
| 2024-08-31 | $0.00 | $67.00K | $1.06B | $344.00K | $-680.22M | $376.86M | 3 month · $920.00K | 3 month · $8.76M | (m) |
| 2024-05-31 | $0.00 | $64.00K | $1.00B | $-135.00K | $-631.26M | $370.69M | 3 month · $1.68M | 3 month · $8.85M | (m) |
| 2024-02-29 | $0.00 | $49.00K | $755.77M | $-350.00K | $-586.72M | $168.75M | (m) | 3 month · $7.82M | (m) |
| 2023-11-30 | $0.00 | $49.00K | $746.30M | $-655.00K | $-545.20M | $200.49M | (m) | 12 month · $33.75M | (m) |
| 2023-08-31 | $0.00 | $49.00K | $738.24M | $-1.23M | $-503.24M | $233.82M | (m) | 3 month · $8.47M | (m) |
| 2023-05-31 | $0.00 | $48.00K | $728.04M | $-1.90M | $-466.26M | $259.92M | (m) | 3 month · $8.75M | (m) |
| 2023-02-28 | $0.00 | $47.00K | $719.24M | $-3.25M | $-441.99M | $274.05M | (m) | 3 month · $8.51M | (m) |
| 2022-11-30 | $0.00 | $47.00K | $709.22M | $-4.32M | $-401.25M | $303.70M | (m) | 12 month · $28.20M | 12 month · $94.76M |
| 2022-08-31 | (m) | $47.00K | $700.77M | $-3.74M | $-354.54M | $342.55M | (m) | 3 month · $6.99M | 3 month · $94.76M |
| 2022-05-31 | (m) | $45.00K | $578.61M | $-3.08M | $-308.83M | $266.74M | (m) | 3 month · $6.78M | (m) |
| 2022-02-28 | (m) | $45.00K | $571.36M | $-2.07M | $-263.43M | $305.92M | (m) | 3 month · $6.07M | (m) |
| 2021-11-30 | $0.00 | $45.00K | $563.76M | $-608.00K | $-220.89M | $342.30M | (m) | 12 month · $15.80M | (m) |
| 2021-08-31 | (m) | $45.00K | $558.42M | $-59.00K | $-183.19M | $375.22M | (m) | 3 month · $4.31M | (m) |
| 2021-05-31 | (m) | $44.00K | $552.46M | $30.00K | $-154.35M | $398.18M | (m) | 3 month · $3.94M | (m) |
| 2021-02-28 | (m) | $39.00K | $398.02M | $49.00K | $-127.97M | $270.13M | (m) | 3 month · $2.70M | (m) |
| 2020-11-30 | (m) | $39.00K | $393.84M | $87.00K | $-103.70M | $290.27M | (m) | 12 month · $4.30M | (m) |
| 2020-08-31 | (m) | $39.00K | $391.23M | $138.00K | $-83.78M | $307.62M | (m) | 3 month · $1.11M | (m) |
| 2020-05-31 | (m) | (m) | (m) | (m) | (m) | $-61.53M | (m) | 3 month · $474.00K | (m) |
| 2020-02-29 | (m) | (m) | (m) | (m) | (m) | $-69.80M | (m) | 3 month · $176.00K | (m) |
| 2019-11-30 | (m) | $4.00K | $2.74M | $-2.00K | $-60.46M | $-57.71M | (m) | 12 month · $510.00K | (m) |
| 2019-08-31 | (m) | (m) | (m) | (m) | (m) | $-44.44M | (m) | 3 month · $136.00K | (m) |
| 2019-05-31 | (m) | (m) | (m) | (m) | (m) | $-42.20M | (m) | 3 month · $105.00K | (m) |
| 2019-02-28 | (m) | (m) | (m) | (m) | (m) | $-39.36M | (m) | 3 month · $102.00K | (m) |
| 2018-11-30 | (m) | (m) | (m) | (m) | (m) | $-36.85M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |